FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386593313> ?p ?o ?g. }

• W4386593313 endingPage "e2332968" @default.
• W4386593313 startingPage "e2332968" @default.
• W4386593313 abstract "Importance Pre-exposure prophylaxis (PrEP) is an important tool for preventing HIV infection. However, PrEP’s impact on cardiometabolic health is understudied. Objective To examine the risk of incident hypertension and statin initiation among adult (age ≥18 years) health plan members starting PrEP with tenofovir alafenamide fumarate (TAF) compared with propensity score–matched adults taking tenofovir disoproxil fumarate (TDF). Design, Setting, and Participants This retrospective cohort study used electronic health records (EHRs) from Kaiser Permanente Southern California. Adult members starting PrEP in Kaiser Permanente Southern California between October 2019 and May 2022 were included. Propensity score matching with multiple imputation (50 matched data sets) was conducted to generate 1 TAF:4 TDF matched data sets with balanced baseline covariates. Exposures PrEP initiation with either TAF or TDF during the study period. Main Outcomes and Measures Incident hypertension and statin initiation within 2 years of PrEP initiation were ascertained through blood pressure and outpatient pharmacy records, respectively. Risk differences and odds ratios (ORs) were estimated using logistic regression and g-computation. Results A total of 6824 eligible individuals were identified (mean [SD] age, 33.9 [10.3] years; 6618 [97%] male). This pool was used to generate 2 cohorts without baseline hypertension or statin use for matching (hypertension: n = 5523; statin: n = 6149) In both cohorts, those starting PrEP with TAF were older and were more likely to be non-Hispanic White compared with those starting with TDF. In matched analysis adjusting for baseline covariates, TAF use was associated with elevated risk of incident hypertension (TAF: n = 371; risk difference, 0.81 [95% CI, 0.12-1.50]; OR, 1.64 [95% CI, 1.05-2.56]). TAF use was also associated with elevated risk of statin initiation (TAF: n = 382; risk difference, 0.85 [95% CI, 0.37-1.33]; OR, 2.33 [95% CI, 1.41-3.85]). Subgroup analyses restricted to individuals 40 years and older at PrEP initiation showed similar results with larger risk difference in statin initiation (risk difference, 4.24 [95% CI, 1.82-6.26]; OR, 3.05 [95% CI, 1.64-5.67]). Conclusions and Relevance In this study of people taking PrEP, TAF use was found to be associated with higher incident hypertension and statin initiation compared with TDF use, especially in those 40 years or older. Continued monitoring of blood pressure and lipids for TAF users is warranted." @default.
• W4386593313 created "2023-09-12" @default.
• W4386593313 creator A5006670620 @default.
• W4386593313 creator A5011715844 @default.
• W4386593313 creator A5029549144 @default.
• W4386593313 creator A5052048899 @default.
• W4386593313 date "2023-09-11" @default.
• W4386593313 modified "2023-10-17" @default.
• W4386593313 title "Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins" @default.
• W4386593313 cites W1577910206 @default.
• W4386593313 cites W1973885323 @default.
• W4386593313 cites W1980040599 @default.
• W4386593313 cites W2066113539 @default.
• W4386593313 cites W2115098571 @default.
• W4386593313 cites W2151009383 @default.
• W4386593313 cites W2152849583 @default.
• W4386593313 cites W2156868587 @default.
• W4386593313 cites W2160704894 @default.
• W4386593313 cites W2168536722 @default.
• W4386593313 cites W2398180202 @default.
• W4386593313 cites W2404984931 @default.
• W4386593313 cites W2592357996 @default.
• W4386593313 cites W2789678217 @default.
• W4386593313 cites W2899244918 @default.
• W4386593313 cites W2912227521 @default.
• W4386593313 cites W2952874474 @default.
• W4386593313 cites W2962964639 @default.
• W4386593313 cites W2986251969 @default.
• W4386593313 cites W2990373619 @default.
• W4386593313 cites W3001764054 @default.
• W4386593313 cites W3011104356 @default.
• W4386593313 cites W3016344065 @default.
• W4386593313 cites W3037133507 @default.
• W4386593313 cites W3045256412 @default.
• W4386593313 cites W3087945560 @default.
• W4386593313 cites W3127127167 @default.
• W4386593313 cites W3151441572 @default.
• W4386593313 cites W3166816047 @default.
• W4386593313 cites W3173796935 @default.
• W4386593313 cites W3175868284 @default.
• W4386593313 cites W3191126387 @default.
• W4386593313 cites W3194679235 @default.
• W4386593313 cites W4230256648 @default.
• W4386593313 cites W4237716864 @default.
• W4386593313 cites W4243620370 @default.
• W4386593313 cites W4283695295 @default.
• W4386593313 cites W4288489469 @default.
• W4386593313 cites W4291020534 @default.
• W4386593313 cites W4295520042 @default.
• W4386593313 cites W4305071849 @default.
• W4386593313 cites W4366992020 @default.
• W4386593313 cites W4376226427 @default.
• W4386593313 doi "https://doi.org/10.1001/jamanetworkopen.2023.32968" @default.
• W4386593313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37695583" @default.
• W4386593313 hasPublicationYear "2023" @default.
• W4386593313 type Work @default.
• W4386593313 citedByCount "0" @default.
• W4386593313 crossrefType "journal-article" @default.
• W4386593313 hasAuthorship W4386593313A5006670620 @default.
• W4386593313 hasAuthorship W4386593313A5011715844 @default.
• W4386593313 hasAuthorship W4386593313A5029549144 @default.
• W4386593313 hasAuthorship W4386593313A5052048899 @default.
• W4386593313 hasBestOaLocation W43865933131 @default.
• W4386593313 hasConcept C120665830 @default.
• W4386593313 hasConcept C121332964 @default.
• W4386593313 hasConcept C126322002 @default.
• W4386593313 hasConcept C142462285 @default.
• W4386593313 hasConcept C151956035 @default.
• W4386593313 hasConcept C156957248 @default.
• W4386593313 hasConcept C17923572 @default.
• W4386593313 hasConcept C203014093 @default.
• W4386593313 hasConcept C2776839432 @default.
• W4386593313 hasConcept C2776939746 @default.
• W4386593313 hasConcept C2776983459 @default.
• W4386593313 hasConcept C2779496540 @default.
• W4386593313 hasConcept C2911190787 @default.
• W4386593313 hasConcept C2993143319 @default.
• W4386593313 hasConcept C3013748606 @default.
• W4386593313 hasConcept C61511704 @default.
• W4386593313 hasConcept C71924100 @default.
• W4386593313 hasConceptScore W4386593313C120665830 @default.
• W4386593313 hasConceptScore W4386593313C121332964 @default.
• W4386593313 hasConceptScore W4386593313C126322002 @default.
• W4386593313 hasConceptScore W4386593313C142462285 @default.
• W4386593313 hasConceptScore W4386593313C151956035 @default.
• W4386593313 hasConceptScore W4386593313C156957248 @default.
• W4386593313 hasConceptScore W4386593313C17923572 @default.
• W4386593313 hasConceptScore W4386593313C203014093 @default.
• W4386593313 hasConceptScore W4386593313C2776839432 @default.
• W4386593313 hasConceptScore W4386593313C2776939746 @default.
• W4386593313 hasConceptScore W4386593313C2776983459 @default.
• W4386593313 hasConceptScore W4386593313C2779496540 @default.
• W4386593313 hasConceptScore W4386593313C2911190787 @default.
• W4386593313 hasConceptScore W4386593313C2993143319 @default.
• W4386593313 hasConceptScore W4386593313C3013748606 @default.
• W4386593313 hasConceptScore W4386593313C61511704 @default.
• W4386593313 hasConceptScore W4386593313C71924100 @default.
• W4386593313 hasIssue "9" @default.

• next